Tirzepatide and semaglutide are the two most-studied incretin peptides, and both are approved medicines — but they work through a different number of receptors. Semaglutide is a single GLP-1 receptor agonist (Ozempic, Wegovy), while tirzepatide activates both the GIP and GLP-1 receptors (Mounjaro, Zepbound). In the trials, that dual mechanism generally translated into larger average weight changes for tirzepatide, though semaglutide has the longer real-world track record. Below we compare mechanism, evidence and the practical differences; we stock the tirzepatide side as a pre-loaded pen.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | Dual agonist: GIP + GLP-1 | Single agonist: GLP-1 |
| Drug class | Incretin (twincretin) GIP/GLP-1 agonist | GLP-1 receptor agonist |
| Regulatory status | Approved (EMA/FDA) | Approved (EMA/FDA) |
| Brand names | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus |
| Trial weight-loss data | ~20–22% at the highest dose (SURMOUNT-1) | ~15% mean in obesity (STEP programme) |
| Dosing frequency | Once weekly (subcutaneous) | Once weekly (subcutaneous); oral form also exists |
| Primary study focus | Glycaemic control (SURPASS) and obesity (SURMOUNT) | Glycaemic control (SUSTAIN) and obesity (STEP) |
| Body Pharm EU availability | Pre-loaded pen (not Mounjaro or Zepbound) | Not stocked by Body Pharm EU |
Semaglutide is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1 to enhance glucose-dependent insulin release, slow gastric emptying and reduce appetite. Tirzepatide does all of that through GLP-1 and adds agonism at the GIP receptor, the second major incretin hormone. Combining the two pathways is the mechanistic rationale for tirzepatide's generally larger effects on weight and glycaemia in head-to-head and cross-trial comparisons, though GIP biology is still an active area of research.
Both compounds are backed by large Phase 3 programmes. Semaglutide's STEP trials reported roughly 15% mean body-weight reduction in obesity, and its SUSTAIN programme established its glycaemic benefit; it also has years of real-world use behind it. Tirzepatide's SURMOUNT-1 reported around 20–22% mean weight reduction at the highest dose, with SURPASS covering glycaemic control in type 2 diabetes. A direct comparison trial (SURMOUNT-5) has also indicated an advantage for tirzepatide on weight endpoints. As always, averages hide wide individual variation and the trials differ in design.
Both are approved, both are dosed once weekly by injection, and both have obesity and diabetes indications — so the core distinction is mechanism and magnitude. Tirzepatide's dual GIP/GLP-1 action is associated with larger average weight changes in the published data, while semaglutide offers a longer real-world safety record and, uniquely, an oral formulation (Rybelsus) alongside the weekly injection. Tolerability and suitability are individual and are matters for a healthcare professional.
We stock tirzepatide as a pre-loaded pen, TIRZEPATIDE 60. It is not Mounjaro or Zepbound and it holds no marketing authorisation. We do not sell semaglutide. This page exists so you can see the full comparison in one place; if your interest is the tirzepatide side, that is the compound we supply.
On the published numbers, tirzepatide tends to produce larger average weight changes thanks to its dual mechanism, while semaglutide brings a broader and longer real-world evidence base and more formulation options. Neither is universally "better"; they represent single-receptor and dual-receptor approaches to the same incretin biology. For an approved treatment, the choice is a clinical one made with a licensed professional — this comparison is educational only.
In the trial data, tirzepatide showed a larger mean weight reduction (~20–22% at the highest dose in SURMOUNT-1) than semaglutide (~15% in the STEP programme), and a direct comparison trial favoured tirzepatide on weight endpoints. Individual responses vary widely, and these are averages from differently designed studies.
Semaglutide targets one receptor (GLP-1); tirzepatide targets two (GIP and GLP-1). That dual mechanism is the main reason tirzepatide is associated with larger effects in the published data.
Yes. Both are approved by the EMA and FDA. Semaglutide is marketed as Ozempic, Wegovy and Rybelsus; tirzepatide as Mounjaro and Zepbound.
No. We stock tirzepatide as a pre-loaded pen but do not carry semaglutide. Our pens are not approved medicines.
Both are given once weekly by subcutaneous injection in their weekly formulations. Semaglutide additionally has an oral daily form (Rybelsus).
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Retatrutide, tirzepatide and semaglutide are the active pharmaceutical ingredients studied in clinical trials; approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
Almost every comparison on this site is indirect: two compounds measured in separate trials, in separate populations, and lined up afterwards. This one is different. Tirzepatide and semaglutide were compared against each other, in the same trial, at the same time. That makes it the strongest comparison we can publish, and worth saying so plainly.
Frías JP, Davies MJ, Rosenstock J et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021. PMID 34170647; SURPASS-2, NCT03987919; Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. PMID 35658024
An open-label, 40-week, phase 3 trial randomising 1,879 patients with type 2 diabetes 1:1:1:1 to tirzepatide at 5 mg, 10 mg or 15 mg, or semaglutide at 1 mg, all once weekly as add-on to metformin.
Tirzepatide was noninferior and superior to semaglutide on mean change in glycated haemoglobin from baseline to week 40, and produced greater weight reduction.
Semaglutide was dosed at 1 mg. That is the licensed dose in that setting; it is not the higher dose used in obesity indications.
So the honest reading is: tirzepatide at up to 15 mg beat semaglutide at 1 mg, in people with type 2 diabetes, over 40 weeks, on glycaemic control. A real superiority finding within those bounds. It is not a general statement that one molecule always outperforms the other at every dose in every population, and a comparison page that drops the comparator dose is not reporting the trial.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is a dual agonist, adding GIP (what tirzepatide is). The receptor-coverage axis organises this whole class and is set out at incretin peptides.
That said, more receptors is not automatically better: each addition is a different pathway rather than more of the same. The reason we can say tirzepatide did better here is the trial, not the mechanism.
This is the pairing where the regulatory point matters most, because both compounds hold EU marketing authorisations. The authorised products are specific formulations at specific strengths, supplied through licensed pharmacies against a prescription, with approved doses, prescribing information and post-marketing surveillance.
A pre-loaded pen containing the same active compound has none of that. Ours is TIRZEPATIDE 60; we do not sell semaglutide. The trial results describe the molecules; they do not describe this supply route. More at why these compounds are not EMA-authorised.
Which is better for an individual, at what dose, and with what tolerance for gastrointestinal adverse events, the characteristic, dose-related pattern for this class. Trial means conceal wide distributions. That decision belongs with a clinician who can prescribe the authorised product.
Related: Retatrutide vs Tirzepatide, Retatrutide vs Semaglutide.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy